— Our expert roundtable discusses how they the treat NSCLC patients who are waiting on NGS results Next-generation sequencing (NGS) is recommended by the National Comprehensive Cancer Network (NCCN) for all patients with non-small cell lung cancer (NSCLC). Several studies at the recent American Society of Clinical Oncology virtual annual meeting explored the application of biomarker testing in the U.S., as well …
At the recent virtual American Society of Clinical Oncology annual meeting, results of the phase III IMpower010 trial demonstrated that adjuvant atezolizumab (Tecentriq) for patients with stage IB to IIIA non-small cell lung cancer (NSCLC) improved disease-free survival in patients with high PD-L1 expression. In this first of four exclusive episodes, MedPage Today brought together three leaders in the field — moderator Vinay Prasad, MD, of the University …
Dr. Anthony Tolcher’s dedication to medical advancements and innovative approaches at NEXT Oncology has earned the practice Best Oncologist in San Antonio in the 2021 Readers’ Choice Awards. NEXT Oncology has made strides in patient care, especially over the past year. As a Phase 1 research center, patient safety is critical. Patients on clinical trials are faced with even greater …
NATIONAL HARBOR, Md. — A novel immunomodulatory therapy demonstrated antitumor activity across a broad range of heavily pretreated, immunotherapy-resistant tumors, including objective responses in advanced non-small cell lung cancer (NSCLC), a preliminary study showed. Treatment with the Siglec-15-targeted monoclonal antibody NC318 led to disease control (response and stable disease) in one-third of the 49 patients on study. The activity included …
Next Oncology, launched a year ago in San Antonio, is moving its headquarters to the Christus Santa Rosa Hospital-Medical Center campus as the phase I cancer research organization advances plans for expansion in the U.S. and abroad. Next Oncology has signed an 11-year lease for nearly 20,000 square feet at Christus’ Medical Center Tower I. It was initially operating in …
Hundreds of cancer drugs are in the pipeline with the potential to save millions of lives, and make even more inroads into this dreaded disease. But may of the tests are stalled, due to a lack of people willing to participate in the clinical trials which are required before a cancer drug can win approval, News Radio 1200 WOAI reports. …
A study by Texas A&M University suggests that we no longer use the phrase ‘cancer survivor’ to refer to former cancer patients, and prominent San Antonio oncologist Dr. Anthony Tolcher agrees, News Radio 1200 WOAI reports. “Many people, it seems, don’t particularly like that term,” said Dr. Tolcher, who is the Director of Clinical Research at Next Oncology and Texas …
July is UV Awareness Month, making it a good time to remind you that one in five Americans will develop skin cancer at some point in their lives. Local doctors are now revealing the research they participated in that found a breakthrough treatment for melanoma. Read more on News 4 San Antonio
ASCO and ASCO’s Conquer Cancer Foundation are proud to recognize the winners of ASCO’s Special Awards, the Society’s highest honors, and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards. The recipients of these awards include researchers, patient advocates, and global oncology leaders who have worked to transform cancer care around the world. ASCO will recognize this year’s awardees, which include a …
On the heels of disclosing last week that the company had adopted a stockholder rights plan – otherwise known as a “poison pill” for protection against hostile takeovers – Durham’s Heat Biologics (Nasdaq: HTBX) and its subsidiary Pelican Therapeutics have recruited some new scientific expertise. Heat disclosed in a filing with the SEC on Monday that medical oncologist Dr. Anthony …
